Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine

[Mingus]

Strange, is that a live vaccine ? , A modified synthethic virus made from a virus ofm an other family ?
It's not clear

___________________


http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum

1: Microbes Infect. 2006 Aug 28; [Epub ahead of print]<SCRIPT language=JavaScript1.2><!--var PopUpMenu2_LocalConfig_jsmenu3Config = [ ["ShowCloseIcon","yes"], ["Help","window.open('/entrez/query/static/popup.html','Links_Help','resizable=no,scrollbars= yes,toolbar=no,location=no,directories=no,status=n o,menubar=no,copyhistory=no,alwaysRaised=no,depend =no,width=400,height=500');"], ["TitleText"," Links "]]var jsmenu3Config = [ ["UseLocalConfig","jsmenu3Config","",""]]//--></SCRIPT><SCRIPT language=JavaScript1.2><!--var Menu16968669 = [ ["UseLocalConfig","jsmenu3Config","",""], ["Books","window.top.location='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=pubmed_AbstractPlus&cmd=Retrieve& db=pubmed&list_uids=16968669&dopt=Books'","",""]]//--></SCRIPT> Links
<DD class=abstract id=abstract16968669>Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.

• Asahi-Ozaki Y,
• Itamura S,
• Ichinohe T,
• Strong P,
• Tamura SI,
• Takahashi H,
• Sawa H,
• Moriyama M,
• Tashiro M,
• Sata T,
• Kurata T,
• Hasegawa H.

Department of Pathology, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.
Attenuated recombinant H5N1 influenza virus was constructed to develop a safe H5N1 influenza vaccine. The immunogenicity and protective effect of the vaccine prepared from haemagglutinin-modified recombinant H5N1 influenza virus was evaluated in mice intranasally co-administered with cholera toxin B subunit containing a trace amount of holotoxin (CTB*), synthetic double-stranded RNA, poly (I:C) or chitin microparticles (CMP) as adjuvants. Intranasal administration of recombinant H5 HA split vaccine with CTB* or poly(I:C) and/or CMP elicited an immunological response with both anti-H5 HA IgA in the nasal wash and anti-H5 HA IgG antibody in the serum, and showed a protective against lethal H5N1 A/Hong Kong/483/97 (HK483) infection. We also demonstrated that intranasal co-administration of antigen with both poly (I:C) and CMP enhanced the expression of Toll-like receptor (TLR) 3, TLR7 in the spleen. These results indicate that poly (I:C) and CMP are highly effective as mucosal adjuvants for use with the nasal H5N1 vaccine.
PMID: 16968669 [PubMed - as supplied by publisher]
</DD>

[gsgs]

Re: Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine

there is this Dk/Hokkaido/Vac-1/04 sequence, which has some deletions
at the cleavage site. Just a guess